AIM
AIM ImmunoTech Inc.1.3800
+0.0600+4.55%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.06MP/E (TTM)
-Basic EPS (TTM)
-18.18Dividend Yield
0%Recent Filings
8-K
Rights offering closes with $1.8M
AIM ImmunoTech closed its rights offering on March 6, 2026, selling 1,842 units of Series G Preferred Stock—each convertible into common at $1.00—and 3,684,000 Class G Warrants exercisable at $1.00 for five years, netting ~$1.8M gross proceeds. Filed Series G designation on March 4. Cash bolsters runway, but warrants add dilution risk.
8-K
Positive DURIPANC interim data
AIM ImmunoTech disclosed positive year-end interim data from the DURIPANC Phase I/II study on February 5, 2026, combining Ampligen with Durvalumab in 18 pancreatic cancer patients post-FOLFIRINOX. The combo proved well-tolerated with just two grade 3 events, sustained high quality of life, and promising PFS/OS trends advancing Phase II enrollment to 25 patients. Immune profiling reveals coordinated innate and adaptive activation. Detailed data due later this year.
8-K
Warrant terms adjusted post-dividend
AIM ImmunoTech adjusted its Class E and F warrants following the January 13, 2026 stock dividend—one share per 1,000 outstanding shares and per eligible option/warrant. Warrants hit the $1.439 floor price after low VWAP in the evaluation period. Shares outstanding now total 5,561,125 each. Adjustments cap further changes.
8-K
Furnished January 2026 presentation
8-K
Annual meeting elects directors
AIM ImmunoTech held its 2025 Annual Meeting on December 16, electing five directors—Nancy K. Bryan, William M. Mitchell, Ted D. Kellner, David I. Chemerow, and Thomas K. Equels—despite significant withhold votes and 833,173 broker non-votes. Stockholders ratified BDO USA as auditors with 1.1M for votes. Say-on-pay failed majority-of-outstanding threshold at 41.4% quorum, yet won votes cast. Board sets annual pay votes.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ALGS
Aligos Therapeutics, Inc.
11.47-0.53
ALT
Altimmune, Inc.
5.03-0.25
AVTX
Avalo Therapeutics, Inc.
18.82+1.12
AXIM
Axim Biotechnologies, Inc.
0.02+0.00
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
IMA
ImageneBio, Inc.
6.25+0.08
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNN
Imunon, Inc.
3.88-0.09
REPL
Replimune Group, Inc.
9.61-0.34